Clinical Trial Update: An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AXS-05 for treatment-resistant depression in treatment-adherent patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• AXS-05 (dextromethorphan-quinidine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Major Depressive Disorder, Treatment Resistant Depression | Phase 2 | Status: UNKNOWN